PURPOSE: Homocysteine is implicated in ganglion cell death associated with glaucoma. To understand mechanisms of homocysteine-induced cell death, we analyzed the sensitivity of the RGC-5 cell line, differentiated using staurosporine, to physiologically-relevant levels of the excitotoxic amino acid homocysteine. METHODS: RGC-5 cells were differentiated 24 hr using 316 nM staurosporine and tested for expression of Thy 1.2 via immunodetection, RT-PCR, and immunoblotting. The sensitivity of staurosporine-differentiated RGC-5 cells to physiological levels of homocysteine (50, 100, 250 microM) and to high levels of homocysteine (1 mM), glutamate (1 mM), and oxidative stress (25 microM:10 mU/ml xanthine:xanthine oxidase) was assessed by TUNEL assay and by immunodetection of cleaved caspase-3. The sensitivity of undifferentiated RGC-5 cells to high (1, 5, and 10 mM) homocysteine was also examined. RESULTS: Undifferentiated RGC-5 cells express Thy 1.2 mRNA and protein. Staurosporine-differentiated RGC-5 cells extend neurite processes and express Thy 1.2 after 24 hr differentiation; they express NF-L after 1 and 3 days differentiation. Treatment of staurosporine -differentiated RGC-5 cells with 50, 100, or 250 microM homocysteine did not alter neurite processes nor induce cell death (detected by TUNEL and active caspase-3) to a level greater than that observed in the control (non-homocysteine-treated, staurosporine-differentiated) cells. The 1 mM dosage of homocysteine in staurosporine-differentiated RGC-5 cells also did not induce cell death above control levels, although 18 hr treatment of non-differentiated RGC-5 cells with 5 mM homocysteine decreased survival by 50%. CONCLUSIONS: RGC-5 cells differentiated for 24 hr with 316 nM staurosporine project robust neurite processes and are positive for ganglion cell markers consistent with a more neuronal phenotype than non-staurosporine-differentiated RGC-5 cells. However, concentrations of homocysteine known to induce ganglion cell death in vivo and in primary ganglion cells are not sufficient to induce death of RGC-5 cells, even when they are differentiated with staurosporine.
PURPOSE:Homocysteine is implicated in ganglion cell death associated with glaucoma. To understand mechanisms of homocysteine-induced cell death, we analyzed the sensitivity of the RGC-5 cell line, differentiated using staurosporine, to physiologically-relevant levels of the excitotoxic amino acid homocysteine. METHODS:RGC-5 cells were differentiated 24 hr using 316 nM staurosporine and tested for expression of Thy 1.2 via immunodetection, RT-PCR, and immunoblotting. The sensitivity of staurosporine-differentiated RGC-5 cells to physiological levels of homocysteine (50, 100, 250 microM) and to high levels of homocysteine (1 mM), glutamate (1 mM), and oxidative stress (25 microM:10 mU/ml xanthine:xanthine oxidase) was assessed by TUNEL assay and by immunodetection of cleaved caspase-3. The sensitivity of undifferentiated RGC-5 cells to high (1, 5, and 10 mM) homocysteine was also examined. RESULTS: Undifferentiated RGC-5 cells express Thy 1.2 mRNA and protein. Staurosporine-differentiated RGC-5 cells extend neurite processes and express Thy 1.2 after 24 hr differentiation; they express NF-L after 1 and 3 days differentiation. Treatment of staurosporine -differentiated RGC-5 cells with 50, 100, or 250 microM homocysteine did not alter neurite processes nor induce cell death (detected by TUNEL and active caspase-3) to a level greater than that observed in the control (non-homocysteine-treated, staurosporine-differentiated) cells. The 1 mM dosage of homocysteine in staurosporine-differentiated RGC-5 cells also did not induce cell death above control levels, although 18 hr treatment of non-differentiated RGC-5 cells with 5 mM homocysteine decreased survival by 50%. CONCLUSIONS:RGC-5 cells differentiated for 24 hr with 316 nM staurosporine project robust neurite processes and are positive for ganglion cell markers consistent with a more neuronal phenotype than non-staurosporine-differentiated RGC-5 cells. However, concentrations of homocysteine known to induce ganglion cell death in vivo and in primary ganglion cells are not sufficient to induce death of RGC-5 cells, even when they are differentiated with staurosporine.
Authors: S Bleich; A Jünemann; N von Ahsen; B Lausen; K Ritter; G Beck; G O H Naumann; J Kornhuber Journal: J Neural Transm (Vienna) Date: 2002-12 Impact factor: 3.575
Authors: Nicole J Van Bergen; John P M Wood; Glyn Chidlow; Ian A Trounce; Robert J Casson; Won-Kyu Ju; Robert N Weinreb; Jonathan G Crowston Journal: Invest Ophthalmol Vis Sci Date: 2009-05-14 Impact factor: 4.799
Authors: Preethi S Ganapathy; Brent Moister; Penny Roon; Barbara A Mysona; Jennifer Duplantier; Ying Dun; Tracy K V E Moister; Marlena J Farley; Puttur D Prasad; Kebin Liu; Sylvia B Smith Journal: Invest Ophthalmol Vis Sci Date: 2009-04-08 Impact factor: 4.799
Authors: R R Krishnamoorthy; P Agarwal; G Prasanna; K Vopat; W Lambert; H J Sheedlo; I H Pang; D Shade; R J Wordinger; T Yorio; A F Clark; N Agarwal Journal: Brain Res Mol Brain Res Date: 2001-01-31
Authors: Roschelle A Heuberger; Alicia I Fisher; Paul F Jacques; Ronald Klein; Barbara E K Klein; Mari Palta; Julie A Mares-Perlman Journal: Am J Clin Nutr Date: 2002-10 Impact factor: 7.045
Authors: Matthew M Harper; Laura Adamson; Bas Blits; Mary Bartlett Bunge; Sinisa D Grozdanic; Donald S Sakaguchi Journal: Exp Eye Res Date: 2009-06-12 Impact factor: 3.467
Authors: Maximillian Schultheiss; Sven Schnichels; Kapka Miteva; Katrin Warstat; Peter Szurman; Martin S Spitzer; Sophie Van Linthout Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-01-06 Impact factor: 3.117
Authors: Preethi S Ganapathy; Richard E White; Yonju Ha; B Renee Bozard; Paul L McNeil; R William Caldwell; Sanjiv Kumar; Stephen M Black; Sylvia B Smith Journal: Invest Ophthalmol Vis Sci Date: 2011-07-25 Impact factor: 4.799